ADMA Stock Analysis: ADMA Biologics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.488m USD | 12M Return: -28.4% | US0008991046 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 29.8M
Qual. Beats: 0
Rev. Trend: 92.0%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
ADMA Biologics, Inc. is a vertically integrated biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics targeting immune deficiencies and infectious diseases. Its operations span two segments: ADMA BioManufacturing and Plasma Collection Centers, reflecting a model that controls the supply chain from raw plasma sourcing through finished product distribution. The companys marketed portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) products for primary humoral immunodeficiency, as well as Nabi-HB, a polyclonal antibody for Hepatitis B exposure. ADMA also maintains a pipeline focused on immunoglobulin-based treatments, including candidates targeting S. pneumoniae infection, and operates its own plasma collection facilities to supply its manufacturing operations. Products are sold through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. The plasma-derived biologics sector is characterized by heavy reliance on limited human plasma supplies, long manufacturing lead times, and regulatory oversight by bodies such as the FDA. ADMA Biologics was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
- ASCENIV and BIVIGAM IVIG sales accelerate revenue growth
- Plasma collection expansion lifts gross margins through vertical integration
- FDA approvals and pipeline progression remain key catalysts
| Net Income: 182.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.18 > 0.02 and ΔFCF/TA 10.98 > 1.0 |
| NWC/Revenue: 92.57% < 20% (prev 70.85%; Δ 21.72% < -1%) |
| CFO/TA 0.19 > 3% & CFO 140.8m > Net Income 182.4m |
| Net Debt (85.5m) to EBITDA (241.3m): 0.35 < 3 |
| Current Ratio: 6.04 > 1.5 & < 3 |
| Outstanding Shares: last quarter (225.8m) vs 12m ago -7.70% < -2% |
| Gross Margin: 68.53% > 18% (prev 54.71%; Δ 13.82% > 0.5%) |
| Asset Turnover: 79.80% > 50% (prev 85.91%; Δ -6.11% > 0%) |
| Interest Coverage Ratio: 22.04 > 6 (EBIT TTM 233.2m / Interest Expense TTM 10.6m) |
| A: 0.66 (Total Current Assets 575.9m - Total Current Liabilities 95.3m) / Total Assets 732.5m |
| B: -0.04 (Retained Earnings -28.6m / Total Assets 732.5m) |
| C: 0.36 (EBIT TTM 233.2m / Avg Total Assets 650.6m) |
| D: 1.49 (Book Value of Equity 438.5m / Total Liabilities 294.0m) |
| Altman-Z'' = 8.15 = AAA |
| DSRI: 1.16 (Receivables 169.2m/137.7m, Revenue 519.2m/488.6m) |
| GMI: 0.80 (GM 54.71% / 68.53%) |
| AQI: 0.75 (AQ_t 0.11 / AQ_t-1 0.15) |
| SGI: 1.06 (Revenue 519.2m / 488.6m) |
| TATA: 0.06 (NI 182.4m - CFO 140.8m) / TA 732.5m) |
| Beneish M = -3.18 (Cap -4..+1) = AA |
As of November 05, 2026, the stock is trading at USD 10.48 with a total of 13,326,974 shares traded. Over the past week, the price has changed by -7.09%, over one month by +3.66%, over three months by +17.62% and over the past year by -28.37%.
Current recommended Stop Loss: 9.40 (which is 10.3% or 2.6 ATR below the current price).
ADMA Biologics has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy ADMA.
- StrongBuy: 2
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 17 | 62.2% |
P/E Trailing = 15.8714
P/E Forward = 11.1607
P/S = 4.8577
P/B = 6.0632
Revenue TTM = 519.2m USD
EBIT TTM = 233.2m USD
EBITDA TTM = 241.3m USD
Long Term Debt = 69.3m USD (from longTermDebt, last fiscal year)
Short Term Debt = 5.40m USD (from shortTermDebt, last quarter)
Debt = 210.1m USD (from shortLongTermDebtTotal, last quarter) + Leases 7.25m
Net Debt = 85.5m USD (calculated: Debt 210.1m - CCE 124.6m)
Enterprise Value = 2.57b USD (2.49b + Debt 210.1m - CCE 124.6m)
Interest Coverage Ratio = 22.04 (Ebit TTM 233.2m / Interest Expense TTM 10.6m)
EV/FCF = 19.37x (Enterprise Value 2.57b / FCF TTM 132.9m)
FCF Yield = 5.16% (FCF TTM 132.9m / Enterprise Value 2.57b)
FCF Margin = 25.60% (FCF TTM 132.9m / Revenue TTM 519.2m)
Net Margin = 35.14% (Net Income TTM 182.4m / Revenue TTM 519.2m)
Gross Margin = 68.53% ((Revenue TTM 519.2m - Cost of Revenue TTM 163.4m) / Revenue TTM)
Gross Margin QoQ = 70.81% (prev 69.36%)
Tobins Q-Ratio = 3.51 (Enterprise Value 2.57b / Total Assets 732.5m)
Interest Expense / Debt = 5.04% (Interest Expense 10.6m / Debt 210.1m)
Taxrate = 22.23% (52.1m / 234.6m)
NOPAT = 181.4m (EBIT 233.2m * (1 - 22.23%))
Current Ratio = 6.04 (Total Current Assets 575.9m / Total Current Liabilities 95.3m)
Debt / Equity = 0.48 (Debt 210.1m / totalStockholderEquity, last quarter 438.5m)
Debt / EBITDA = 0.35 (Net Debt 85.5m / EBITDA 241.3m)
Debt / FCF = 0.64 (Net Debt 85.5m / FCF TTM 132.9m)
Total Stockholder Equity = 428.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 28.04% (Net Income 182.4m / Total Assets 732.5m)
RoE = 42.56% (Net Income TTM 182.4m / Total Stockholder Equity 428.6m)
RoCE = 46.84% (EBIT 233.2m / Capital Employed (Equity 428.6m + L.T.Debt 69.3m))
RoIC = 29.42% (NOPAT 181.4m / Invested Capital 616.7m)
WACC = 6.38% (E(2.49b)/V(2.70b) * Re(6.59%) + D(210.1m)/V(2.70b) * Rd(5.04%) * (1-Tc(0.22)))
Discount Rate = 6.59% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -71.64 | Cagr: -3.06%
[DCF] Terminal Value 77.97% ; FCFF base≈96.0m ; Y1≈110.1m ; Y5≈162.0m
[DCF] Fair Price = 10.50 (EV 2.44b - Net Debt 85.5m = Equity 2.35b / Shares 224.0m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 92.02 | Revenue CAGR: 28.51% | SUE: 0.27 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.20 | Chg30d=+0.00% | Revisions=-50% | Analysts=3
EPS current Year (2026-12-31): EPS=0.80 | Chg30d=+0.00% | Revisions=-50% | GrowthEPS=+21.3% | GrowthRev=+4.9%
EPS next Year (2027-12-31): EPS=0.94 | Chg30d=+0.00% | Revisions=-50% | GrowthEPS=+18.4% | GrowthRev=+17.6%
[Analyst] Revisions Ratio: -75% (up=0, down=9)